ViGuard Health says in a petition that with two IND programs for studies of pyridoxamine's potential therapeutic use formally withdrawn, FDA should rescind its 2009 decision that it did not qualify as a dietary ingredient.

Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.

First-cycle approvals took longer than multi-cycle approvals in the generic drug user fee program's first year, but decreased dramatically in year two.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2015.